Highlights: AI/ML’s subsidiary, Tech2heal, expands its global footprint with second clinical trial contract – conducted jointly by French and Italian University Hospitals. The clinical trial is funded by a European Commission fund. The study includes […]
Highlights: The clinical study, led by the University Hospital of Nice, France involves 30,000 patients. AI/ML Innovations’ subsidiary, Tech2Heal, has been chosen to provide the “technological backbone” for the study. Tech2heal has been awarded a […]
Vancouver, British Columbia–April 26, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory […]
Vancouver, British Columbia– – April 18, 2023- Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for […]
Vancouver, British Columbia– April 11, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for […]
Health Coach has functionality similar to ChatGPT, but is designed to monitor and manage the users health. Health Coach provides conversational personal health goal setting and care recommendations by directly accessing and utilizing a user’s […]
NEXT SUPER STOCK Nova Mentis Life Sciences (OTC: NMLSF) Psilocybin for Autism FXS – Patient Enrollment for Phase 2A Clinical Trials Update
Vancouver, British Columbia— April 5, 2023- Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory […]
Vancouver, British Columbia–March 29, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory […]
The Study, Led by the University Hospital of Nice, France Involves 30,000 Patients Tech2Heal’s Platform has been chosen as the technological backbone for the Study 3.4million Europeans live in assisted-care facilities, and 101million are 65 […]
TORONTO, ON /March 6, 2023 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to report that its wholly owned subsidiary, Health […]
TORONTO, ON / February 2, 2023 / AI/ML Innovations Inc. (“AIML”) (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that its minority-owned […]
Teladoc Health (NYSE: TDOC) Earnings Call Q3 2022 Highlights CEO Jason Gorevic: Teladoc Health reported strong third quarter results driven by solid execution across the business. Revenue grew 17% over the prior years to […]
The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome Vancouver, British Columbia–(Newsfile Corp. – December 22, 2022) – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) […]
Microdose Treatment Modulates Cognition Vancouver, British Columbia— December 8, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
